GMAB Stock: Genmab A/S Stock Price, Analysis & Insights
Get live GMAB stock price $24.64, comprehensive Genmab A/S stock analysis, charts, news, and expert forecast. Real-time GMAB stock data and investment insights.
Loading chart data...
Genmab A/S (GMAB) Overview
Genmab A/S (GMAB) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, GMAB trades at $24.64 with a market capitalization of 15.13B . Over the past 52 weeks, GMAB has traded between $20.23 and $35.43 , with the current price positioned at approximately 29% of this range . The stock currently trades at a price-...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 15.13B
- Current price: $24.64
- 52-week range: $20.23 - $35.43
- P/E ratio: 18.67
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The com...
Company Information
- CEO
- Jan van de Winkel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2638
Contact Information
- Website
- https://www.genmab.com
- Address
- Kalvebod Brygge 43
- Country
- DK
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 18.7)
✓ Lower volatility stock (Beta: 0.68) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Genmab A/S shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Genmab A/S
- ⚠Investors should consider how Genmab A/S fits within their overall portfolio allocation
Market Cap
15.13B
P/E Ratio (TTM)
18.67
Beta
0.68
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare GMAB with peer companies:
- Price
- $203.43
- Market cap
- 22.52B
- Price
- $52.95
- Market cap
- 13.31B
- Price
- $164.09
- Market cap
- 24.83B
- Price
- $105.43
- Market cap
- 21.06B
- Price
- $28.71
- Market cap
- 20.65B
- Price
- $54.72
- Market cap
- 23.54B
- Price
- $12.68
- Market cap
- 9.83B
- Price
- $163.00
- Market cap
- 14.04B
- Price
- $542.41
- Market cap
- 23.02B
- Price
- $89.31
- Market cap
- 17.28B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.